Interventional device developer Guidant has begun a new clinical trial to determine the safety and efficacy of renal artery stenting in hypertensive patients.
The study, known as the Herculink Multicenter Evaluation of Renal Stenting (HERMES), is a prospective, non-randomized trial that will enroll approximately 250 patients who have had unsatisfactory results from angioplasty to treat blockages in renal arteries. Twenty-five sites in the U.S. will participate, and Guidant’s Rx Herculink 14 peripheral stent system will be the only device deployed, according to the Indianapolis-based firm.
Herculink is currently being marketed for peripheral vascular indications in Europe, as well as in non-European countries that base regulatory approval for medical devices on the European CE Mark. It is currently approved in the U.S. and Canada for the treatment of malignant biliary duct obstructions.
By AuntMinnie.com staff writersAugust 30, 2000
Related Reading
Boston Scientific, Guidant bury hatchet, May 17, 2000
Copyright © 2000 AuntMinnie.com
